SIRPA and neoplasm: Consequently, rather than modulating accumulation of myeloid cells to impact tumor clearance, SIRPα blockade instead favors myeloid reprogramming to drive activation and tumoricidal function of other infiltrating populations, such as CD8 T cells and cDC1s.